Effect of high-dose rosuvastatin loading before percutaneous coronary intervention in female patients with non-ST-segment elevation acute coronary syndrome
查看参考文献20篇
文摘
|
Background Early loading statin therapy before percutaneous coronary intervention (PCI) is associated with reduced mortality and periprocedural myocardial injury. The aim of this study was to study the effect of rosuvastatin loading therapy before PCI in female patients with non-ST-segment elevation acute coronary syndrome (NSTEACS). Methods Consecutive 117 female patients with NSTEACS were randomly assigned to either the group of rosuvastatin loading before PCI (20 mg 12 hours before angioplasty procedure, with a further 10 mg dose 2 hours before procedure, the loading dose group, n=59) or the no rosuvastatin treatment group before PCI (control group, n=58). Periprocedural myocardial injury, periprocedural changes of high sensitivity C-reactive protein (hs-CRP), interleukin (IL)-1, IL-6, and tumor necrosis factor (TNF)-a in serum and the incidence of major adverse cardiac events (MACE) 3 months and 6 months later were assessed. Results The incidence of periprocedural myocardial injury was higher in control group than loading dose group (CKMB: 10.17% vs. 25.86%, P=0.027; Troponin I: 11.86% vs. 29.31%, P=0.019). MACE occurred in 1.69% of patients in loading dose group and 12.07% of those in control group 3 months after procedure (P=0.026), 3.39% vs. 17.24% at 6 months (P=0.014). The levels of hs-CRP, IL-1, IL-6, and TNF-a in serum were not significantly different between the two groups before PCI, but after PCI they were significantly higher in control group. Conclusions High-dose rosuvastatin loading before PCI significantly reduced periprocedural myocardial injury and periprocedural inflammation cytokines release and improved 3-month and 6-month clinical outcomes in female patients with NSTEACS who underwent PCI. |
来源
|
Chinese Medical Journal
,2012,125(13):2250-2254 【核心库】
|
DOI
|
10.3760/cma.j.issn.0366-6999.2012.13.002
|
关键词
|
rosuvastatin
;
acute coronary syndrome
;
angioplasty
;
female
;
inflammation
|
地址
|
Department of Cardiology, First Affiliated Hospital of China Medical University, Liaoning, Shenyang, 110001
|
语种
|
英文 |
文献类型
|
研究性论文 |
ISSN
|
0366-6999 |
学科
|
中国医学 |
文献收藏号
|
CSCD:4573015
|
参考文献 共
20
共1页
|
1.
Blomkalns A L. For the CRUSADE Investigators: Gender disparities in the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: large-scale observations from the CRUSADE (Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the American College of Cardiology/American Heart Association Guidelines) National Quality Improvement Initiative.
J Am Coll Cardiol,2005,45:832-837
|
被引
2
次
|
|
|
|
2.
Schwartz G G. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial.
JAMA,2001,285:1711-1718
|
被引
91
次
|
|
|
|
3.
Ray K K. Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial.
J Am Coll Cardiol,2005,46:1405-1410
|
被引
6
次
|
|
|
|
4.
Patti G. Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial.
J Am Coll Cardiol,2007,49:1272-1278
|
被引
75
次
|
|
|
|
5.
Yun K H. Effect of additional statin therapy on endothelial function and prognosis in patients with vasospastic angina.
Korean Circ J,2008,38:638-643
|
被引
2
次
|
|
|
|
6.
Nishino M. Preprocedural statin administration can reduce thrombotic reaction after stent implantation.
Circ J,2008,72:232-237
|
被引
3
次
|
|
|
|
7.
Thygesen K. On behalf of the joint ESC/ACCF/AHA/WHF task force for the redefinition of myocardial infarction. Universal definition of myocardial infarction.
J Am Coll Cardiol,2007,50:2173-2195
|
被引
72
次
|
|
|
|
8.
Libby P. Pathophysiology of coronary artery disease.
Circulation,2005,111:3481-3488
|
被引
61
次
|
|
|
|
9.
Hansson G K. Immune mechanisms in atherosclerosis.
Arterioscler Thromb Vasc Biol,2001,21:1876-1890
|
被引
50
次
|
|
|
|
10.
Rus H G. Interleukin-6 and interleukin-8 protein and gene expression in human arterial atherosclerotic wall.
Atherosclerosis,1996,127:263-271
|
被引
19
次
|
|
|
|
11.
Buffon A. Widespread coronary inflammation in unstable angina.
N Engl J Med,2002,347:5-12
|
被引
28
次
|
|
|
|
12.
Balbay Y. Circulating IL-1 beta, IL-6, TNF alpha and soluble ICAM-1 in patients witch chronic stable angina and myocardial infarction.
Angiology,2001,52:109-114
|
被引
14
次
|
|
|
|
13.
Bonz A W. Cytokine response after percutaneous coronary intervention in stable angina: effect of selective glycoprotein IIb/IIIa receptor antagonism.
Am Heart J,2003,145:693-699
|
被引
8
次
|
|
|
|
14.
Abdelmeguid A E. Significance of mild transient release of creatine-kinase MB fraction after percutaneous coronary interventions.
Circulation,1996,94:1528-1536
|
被引
10
次
|
|
|
|
15.
Morikawa S. The effect of statins on mRNA levels of genes related to inflammation, coagulation, and vascular constriction in HUVEC. Human umbilical vein endothelial cells.
J Atheroscler Thromb,2002,9:178-183
|
被引
7
次
|
|
|
|
16.
Stenestrand U. Early statin treatment following acutemyocardial infarction and 1-year survival.
JAMA,2001,285:430-436
|
被引
13
次
|
|
|
|
17.
Cannon C P. Intensive versus moderate lipid lowering with statins after acute coronary syndromes.
N Eng J Med,2004,350:1495-1504
|
被引
132
次
|
|
|
|
18.
Sun Y. Effect of different loading doses of atorvastatin on percutaneous coronary intervention for acute coronary syndromes.
Can J Cardiol,2010,26:481-485
|
被引
8
次
|
|
|
|
19.
Yun K H. The beneficial effect of high loading dose of rosuvastatin before percutaneous coronary intervention in patients with acute coronary syndrome.
Int J Cardiol,2009,137:246-251
|
被引
15
次
|
|
|
|
20.
Sposito A C. Statin therapy in acute coronary syndromes. Mechanistic insight into clinical benefit.
Arterioscler Thromb Vasc Biol,2002,22:1524-1534
|
被引
7
次
|
|
|
|
|